|  
Home
Provigil Information
A Solution for Sleepiness
Taking Provigil
Off-Label Provigil
Use
Journal Articles
Related Resources
Provigil in the News
About Provigil Web
|
 |
 |
 |

Sleep Medicine Reviews
Volume 8, Issue 5 , October 2004, Pages 339-354
Dev Banerjeea, Michael V. Vitiellob and Ronald R. Grunstein
Pharmacotherapy for excessive daytime sleepiness
Excessive daytime sleepiness (EDS) has recognized detrimental consequences
such as road traffic accidents, impaired psychological functioning and
reduced work performance. EDS can result from multiple causes such as
sleep deprivation, sleep fragmentation, neurological, psychiatric and
circadian rhythm disorders. Treating the underlying cause of EDS remains
the mainstay of therapy but in those who continue to be excessively sleepy,
further treatment may be warranted. Traditionally, the amphetamine derivatives,
methylphenidate and pemoline (collectively sympathomimetic) psychostimulants
were the commonest form of therapy for EDS, particularly in conditions
such as narcolepsy.
More recently, the advent of modafinil has broadened the range of therapeutic
options. Modafinil has a safer side-effect profile and as a result, interest
in this drug for the management of EDS in other disorders, as well as
narcolepsy, has increased considerably.
There is a growing school of thought that modafinil may have
a role to play in other indications such as obstructive sleep apnea/hypopnea
syndrome already treated by nasal continuous positive airway
pressure but persisting EDS, shift work sleep disorders,
neurological causes of sleepiness, and healthy adults performing sustained
operations, particularly those in the military. However, until adequately
powered randomised-controlled trials confirm long-term efficacy and safety,
the recommendation of wakefulness promoters in healthy adults cannot be
justified.
|
|